Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs?

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Expert Opinion on Therapeutic Patents

• Publication date

  2002-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1517/13543776.12.10.1527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation

  2002cited by this paper
• Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease.

  2002cited by this paper
• Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection.

  2002cited by this paper
• Prevalence of bipolar disorder: a further study in The Netherlands.

  2002cited by this paper
• Cytokine modulators as novel therapies for asthma.

  2002cited by this paper
• The GSK3β signaling cascade and neurodegenerative disease

  2002cited by this paper
• Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β

  2002cited by this paper
• First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.

  2002cited by this paper
• Non-cholinergic pharmacotherapy approaches to the future treatment of Alzheimer's disease.

  2002cited by this paper
• P24, a glycogen synthase kinase 3 (GSK 3) inhibitor.

  2002cited by this paper
• Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease

  2001cited by this paper
• Structure of GSK3β reveals a primed phosphorylation mechanism

  2001cited by this paper
• GSK3 takes centre stage more than 20 years after its discovery.

  2001cited by this paper
• Glycogen synthase kinase-3: properties, functions, and regulation.

  2001cited by this paper
• Crystal Structure of Glycogen Synthase Kinase 3β: Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition

  2001cited by this paper
• The renaissance of GSK3

  2001cited by this paper
• Tau and transgenic animal models.

  2001cited by this paper
• Selective small‐molecule inhibitors of glycogen synthase kinase‐3 activity protect primary neurones from death

  2001cited by this paper
• The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.

  2001cited by this paper
• The molecular bases of Alzheimer's disease and other neurodegenerative disorders.

  2001cited by this paper
• Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

  2001cited by this paper
• Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice

  2001cited by this paper
• 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3).

  2001cited by this paper
• The Structure of Phosphorylated GSK-3β Complexed with a Peptide, FRATtide, that Inhibits β-Catenin Phosphorylation

  2001cited by this paper
• N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors.

  2000cited by this paper
• Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.

  2000cited by this paper
• Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent.

  2000cited by this paper
• Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimer’s disease and other neurodegenerative disorders

  2000cited by this paper
• Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.

  1999cited by this paper
• The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31‐8220) are potent inhibitors of glycogen synthase kinase‐3 activity

  1999cited by this paper
• Synthesis and Potential Muscarinic Receptor Binding and Antioxidant Properties of 3‐(Thiadiazolyl)pyridine 1‐Oxide Compounds

  1999cited by this paper
• Expression analysis of glycogen synthase kinase-3 in human tissues.

  1999cited by this paper
• GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis.

  1998cited by this paper
• The Natural Product Hymenialdisine Inhibits Interleukin-8 Production in U937 Cells by Inhibition of Nuclear Factor-κB

  1997cited by this paper
• Arylimino-1,2,4-thiadiazolidinones: a new family of potassium channel openers.

  1997cited by this paper
• Experimentally Induced Benignancy of Neoplasm. V. The Influence of Hormones on the Host's Resistance to Implanted Neoplasm

  1941cited by this paper

• Glycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019–2024)

  2025cites this paper
• An updated research of glycogen synthase kinase-3β inhibitors: a review

  2021cites this paper
• Targeting Glycogen Synthase Kinase-3 (Gsk3β) With Naturally Occurring Phytochemicals (Quercetin and its Modelled Analogue): A Pharmacophore Modelling and Molecular Docking Approach

  2020cites this paper
• Novel meriolin derivatives as rapid apoptosis inducers.

  2019cites this paper
• Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review.

  2019cites this paper
• DEVELOPMENT OF BIOANALYTICAL METHODS FOR QUANTITATIVE MEASUREMENT OF ANTICANCER AGENTS

  2018cites this paper
• Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.

  2018cites this paper
• Development and validation of an LC–MS/MS method for quantitative determination of GS87, a novel antineoplastic agent, in mouse plasma

  2018cites this paper
• 3D-QSAR and Molecular Docking Study on Maleimide-Based Glycogen Synthase Kinase 3 (GSK-3) Inhibitors as Stimulators of Steroidogenesis

  2018cites this paper
• In-Silico Approach Towards Protein Targets Related to Diabetes Mellitus-An Overview

  2017cites this paper
• Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015)

  2017cites this paper
• Inhibition mechanism of CDK-2 and GSK-3β by a sulfamoylphenyl derivative of indoline—a molecular dynamics study

  2017cites this paper
• Molecular dynamics study on inhibition mechanism of CDK-2 and GSK-3β by CHEMBL272026 molecule

  2016cites this paper
• Molecular dynamics study of the inhibitory effects of ChEMBL474807 on the enzymes GSK-3β and CDK-2

  2015cites this paper
• Pharmacophore approaches in protein kinase inhibitors design

  2014cites this paper
• Benzimidazole-biologically attractive scaffold for protein kinase inhibitors

  2014cites this paper
• Ligand-based pharmacophore detection, screening of potential pharmacophore and docking studies, to get effective glycogen synthase kinase inhibitors

  2013influential citation
• Design of glycogen synthase kinase-3 inhibitors: an overview on recent advancements.

  2013cites this paper
• Synthesis of 4-benzyl-3-phenylbutenolide natural products

  2013cites this paper
• Binding of BIS like and other ligands with the GSK-3β kinase: a combined docking and MM-PBSA study

  2012cites this paper
• Chapter 6: Bibliography

  2012cites this paper
• Microwave-assisted synthesis of novel bis(2-thioxothiazolidin-4-one) derivatives as potential GSK-3 inhibitors

  2012cites this paper
• Role of bridging water molecules in GSK3β‐inhibitor complexes: Insights from QM/MM, MD, and molecular docking studies

  2011cites this paper
• Synthesis and biological evaluation of new penta- and heptacyclic indolo- and quinolinocarbazole ring systems obtained via Pd(0) catalysed reductive N-heteroannulation.

  2010cites this paper
• Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models.

  2009cites this paper
• Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation

  2009cites this paper
• Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.

  2008cites this paper
• Preclinical efficacy on GSK‐3 inhibitors: Towards a future generation of powerful drugs

  2008cites this paper
• QSAR Models for Prediction of Glycogen Synthase Kinase‐3β Inhibitory Activity of Indirubin Derivatives

  2008cites this paper
• Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors.

  2008cites this paper
• Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.

  2007cites this paper
• SOURCE FOR GLYCOGEN SYNTHASE KINASE 3 INHIBITORS

  2006cites this paper
• An efficient protocol for solid phase aminothiazole synthesis

  2006cites this paper
• Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder.

  2006cites this paper
• The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3

  2005cites this paper
• SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.

  2005cites this paper
• Mood stabilizers target cellular plasticity and resilience cascades

  2005cites this paper
• New 2-bromomethyl-8-substituted-benzo[c]chromen-6-ones. Synthesis and biological properties.

  2005cites this paper
• Chapter 3 – Applied Suzuki cross-coupling reaction for syntheses of biologically active compounds

  2005cites this paper
• In Vivo Evidence in the Brain for Lithium Inhibition of Glycogen Synthase Kinase-3

  2004cites this paper
• 3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.

  2004cites this paper
• Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3β (GSK-3β) inhibitors☆

  2004cites this paper
• Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3β (GSK-3β) inhibitors

  2004cites this paper
• Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.

  2004cites this paper
• Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

  2004cites this paper
• 6-heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3).

  2003cites this paper
• Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.

  2003cites this paper
• GSK-3-selective inhibitors derived from Tyrian purple indirubins.

  2003cites this paper